by Stacey Hawkins | May 25, 2017 | Immunotherapies
The Drug Kingpins Monoclonal antibodies (mAbs) are the undisputed drug kingpins. In 2013, the mAb market raked in $75 billion in combined sales, covering a whole range of indications from cancer and infectious disease, to autoimmune disorders, and even high... 
by Stacey Hawkins | Mar 9, 2017 | Immunotherapies
Basics & Innovations Monoclonal antibody (mAb) therapeutics burst onto the healthcare scene 20 years ago, and today they remain one of the most versatile and effective therapeutics available. The tried and true mAbs are still in high demand, and we suspect this... 
by Stacey Hawkins | May 19, 2016 | Uncategorized
BIOPHARMA’S DARLING Immunotherapy is the current biopharma darling, garnering massive investment and media attention. Ranging from monoclonal antibodies to engineered T-cells, companies are rapidly learning how to harness the power of the immune system to fight... 
by Stacey Hawkins | May 12, 2016 | Oncology
Pushing the Self-Destruct Button Breakthrough drug Venclexta charged onto the marketplace three months early to battle chronic lymphocytic leukemia. AbbVie’s (North Chicago, IL) and Roche’s (Basel, Switzerland) new therapy gained a quick approval after 80% of... 
by Stacey Hawkins | Dec 10, 2015 | Other Diagnostics
The Latest In Cancer Diagnostics Hearing the words “it might be cancer” paired with your doctor’s perplexed look is enough to send shockwaves through your body. Getting to the heart of a diagnosis usually requires a surgical biopsy—removal and...
